Pasar al contenido principal

INDUCCION DE TOLERANCIA INMUNOLOGICA: NUEVAS VIAS Y DIANAS TERAPEUTICAS

PI17/01521

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2017
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO INV GERMANS TRIAS I PUJOL
Centro realización INSTITUTO DE INVESTIGACION GERMANS TRIAS I PUJOL (IGTP)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Targeting aryl hydrocarbon receptor functionally restores tolerogenic dendritic cells derived from patients with multiple sclerosis

  • Fondelli, Federico|||0000-0002-6875-4744
  • Willemyns, Jana|||0000-0001-6325-9309
  • Domenech-Garcia, Roger|||0009-0002-5742-566X
  • Mansilla, Maria José
  • Godoy-Tena, Gerard|||0000-0003-3832-5794
  • Ferreté-Bonastre, Anna G.|||0000-0003-3327-6129
  • Agúndez-Moreno, Alex|||0009-0000-9524-235X
  • Presas Rodríguez, Sílvia|||0000-0001-8545-2476
  • Ramo-Tello, Cristina|||0000-0001-8643-5053
  • Ballestar, Esteban|||0000-0002-1400-2440
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
Multiple sclerosis (MS) is a chronic disease characterized by dysregulated self-reactive immune responses that damage the neurons' myelin sheath, leading to progressive disability. The primary therapeutic option, immunosuppressants, inhibits pathogenic anti-myelin responses but depresses the immune system. Antigen-specific monocyte-derived autologous tolerogenic dendritic cells (tolDCs) offer alternative therapeutic approaches to restore tolerance to autoantigens without causing generalized immunosuppression. However, immune dysregulation in MS could impact the properties of the monocytes used as starting material for this cell therapy. Here, we characterized CD14+ monocytes, mature dendritic cells, and vitamin D3-tolDCs (VitD3-tolDCs) from active, treatment-naive MS patients and healthy donors (HDs). Using multiomics, we identified a switch in these cell types toward proinflammatory features characterized by alterations in the aryl hydrocarbon receptor (AhR) and NF-κB pathways. MS patient-derived VitD3-tolDCs showed reduced tolerogenic properties compared with those from HDs, which were fully restored through direct AhR agonism and by use of in vivo or in vitro dimethyl fumarate (DMF) supplementation. Additionally, in the experimental autoimmune encephalomyelitis mouse model, combined therapy of DMF and VitD3-tolDCs was more efficient than monotherapies in reducing the clinical score of mice. We propose that a combined therapy with DMF and VitD3-tolDCs offers enhanced therapeutic potential in treating MS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Combined Therapy of Vitamin D3-Tolerogenic Dendritic Cells and Interferon-β in a Preclinical Model of Multiple Sclerosis

  • Quirant, Bibiana|||0000-0002-3875-8074
  • Mansilla Lopez, Maria Jose|||0000-0002-5044-6313
  • Navarro-Barriuso, Juan|||0000-0003-2884-4961
  • Presas Rodríguez, Sílvia|||0000-0001-8545-2476
  • Teniente Serra, Aina|||0000-0003-3440-804X
  • Fondelli, Federico|||0000-0002-6875-4744
  • Ramo-Tello, Cristina|||0000-0001-8643-5053
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
Autologous antigen-specific therapies based on tolerogenic dendritic cells (tolDC) offer the possibility to treat autoimmune diseases by restoring homeostasis and targeting specifically autoreactive responses. Here, we explore the hypothesis that systemic inflammation occurring in autoimmune diseases, such as multiple sclerosis (MS), can generate a disease-specific environment able to alter the functionality of tolDC. In this context in fact, a combined therapy of tolDC with an immunomodulatory treatment could potentiate the beneficial effect of this antigen-specific cell therapy. For this purpose, we analyzed the efficacy of a combined therapy based on the use of vitamin D3 (VitD3)-tolDC plus interferon beta (IFN-beta) in MS. VitD3-tolDC were generated from healthy donors and MS patients and co-cultured with allogeneic peripheral blood mononuclear cells, in the presence or absence of IFN-beta. In vitro, VitD3-tolDC treatment reduced the percentage of activated T cells and allogeneic proliferation, whereas VitD3-tolDC+IFN-beta treatment enhanced the suppressive ability of VitD3-tolDC and, additionally, induced a shift towards a Th2 profile. To determine the clinical benefit of the combined therapy, C57BL/6-experimental autoimmune encephalomyelitis (EAE)-induced mice were treated with antigen-specific VitD3-tolDC and/or IFN-beta. Treatment of EAE mice with combined therapy ameliorated the disease course compared to each monotherapy. These results suggest that a combined therapy based on antigen-specific VitD3-tolDC and IFN-beta may represent a promising strategy for MS patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Ways forward for tolerance-inducing cellular therapies- An afactt perspective

  • Ten Brinke, Anja
  • Martinez-Llordella, Marc
  • Cools, Nathalie|||0000-0002-0459-901X
  • Hilkens, Catharien M. U.
  • van Ham, S. Marieke
  • Sawitzki, Birgit
  • Geissler, Edward K.
  • Lombardi, Giovanna
  • Trzonkowski, Piotr
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
Clinical studies with cellular therapies using tolerance-inducing cells, such as tolerogenic antigen-presenting cells (tolAPC) and regulatory T cells (Treg) for the prevention of transplant rejection and the treatment of autoimmune diseases have been expanding the last decade. In this perspective, we will summarize the current perspectives of the clinical application of both tolAPC and Treg, and will address future directions and the importance of immunomonitoring in clinical studies that will result in progress in the field.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

MAP7 and MUCL1 are biomarkers of Vitamin D3-induced tolerogenic dendritic cells in multiple sclerosis patients

  • Navarro-Barriuso, Juan|||0000-0003-2884-4961
  • Mansilla Lopez, Maria Jose|||0000-0002-5044-6313
  • Quirant, Bibiana|||0000-0002-3875-8074
  • Ardiaca-Martínez, Alicia
  • Teniente Serra, Aina|||0000-0003-3440-804X
  • Presas Rodríguez, Sílvia|||0000-0001-8545-2476
  • Ten Brinke, Anja
  • Ramo-Tello, Cristina|||0000-0001-8643-5053
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
The administration of autologous tolerogenic dendritic cells (tolDC) has become a promising alternative for the treatment of autoimmune diseases, such as multiple sclerosis (MS). Specifically, the use of vitamin D3 for the generation of tolDC (vitD3-tolDC) constitutes one of the most widely studied approaches, as it has evidenced significant immune regulatory properties, both in vitro and in vivo. In this article, we generated human vitD3-tolDC from monocytes from healthy donors and MS patients, characterized in both cases by a semi-mature phenotype, secretion of IL-10 and inhibition of allogeneic lymphocyte proliferation. Additionally, we studied their transcriptomic profile and selected a number of differentially expressed genes compared to control mature and immature dendritic cells for their analysis. Among them, qPCR results validated CYP24A1, MAP7 and MUCL1 genes as biomarkers of vitD3-tolDC in both healthy donors and MS patients. Furthermore, we constructed a network of protein interactions based on the literature, which manifested that MAP7 and MUCL1 genes are both closely connected between them and involved in immune-related functions. In conclusion, this study evidences that MAP7 and MUCL1 constitute robust and potentially functional biomarkers of the generation of vitD3-tolDC, opening the window for their use as quality controls in clinical trials for MS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Ethyl Pyruvate Induces Tolerogenic Dendritic Cells

  • Djedovic, Neda
  • Mansilla Lopez, Maria Jose|||0000-0002-5044-6313
  • Jevtić, Bojan
  • Navarro-Barriuso, Juan|||0000-0003-2884-4961
  • Saksida, Tamara
  • Martínez-Cáceres, Eva M.
  • Miljković, Ðorđe
Dendritic cells (DC) are professional antigen presenting cells that have a key role in shaping the immune response. Tolerogenic DC (tolDC) have immuno-regulatory properties and they are a promising prospective therapy for multiple sclerosis and other autoimmune diseases. Ethyl pyruvate (EP) is a redox analog of dimethyl fumarate (Tecfidera), a drug for multiple sclerosis treatment. We have recently shown that EP ameliorates experimental autoimmune encephalomyelitis, a multiple sclerosis murine model. Here, we expanded our study to its tolerogenic effects on DC. Phenotypic analysis has shown that DC obtained from mice or humans reduce expression of molecules required for T cell activation such as CD86, CD83, and HLA-DR under the influence of EP, while CD11c expression and viability of DC are not affected. Furthermore, EP-treated DC restrain proliferation and modulate cytokine production of allogeneic lymphocytes. These results demonstrate that EP has the ability to direct DC toward tolDC.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Paving the way towards an effective treatment for multiple sclerosis, advances in cell therapy

  • Mansilla Lopez, Maria Jose|||0000-0002-5044-6313
  • Presas Rodríguez, Sílvia|||0000-0001-8545-2476
  • Teniente Serra, Aina|||0000-0003-3440-804X
  • González-Larreategui, Íñigo|||0000-0002-0959-8497
  • Quirant, Bibiana|||0000-0002-3875-8074
  • Fondelli, Federico|||0000-0002-6875-4744
  • Djedovic, Neda
  • Iwaszkiewicz-Grzes, Dorota|||0000-0003-1177-1874
  • Chwojnicki, K.
  • Miljković, Đ.
  • Trzonkowski, P.
  • Ramo-Tello, Cristina|||0000-0001-8643-5053
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
Multiple sclerosis (MS) is a leading cause of chronic neurological disability in young to middle-aged adults, affecting ~2.5 million people worldwide. Currently, most therapeutics for MS are systemic immunosuppressive or immunomodulatory drugs, but these drugs are unable to halt or reverse the disease and have the potential to cause serious adverse events. Hence, there is an urgent need for the development of next-generation treatments that, alone or in combination, stop the undesired autoimmune response and contribute to the restoration of homeostasis. This review analyzes current MS treatments as well as different cell-based therapies that have been proposed to restore homeostasis in MS patients (tolerogenic dendritic cells, regulatory T cells, mesenchymal stem cells, and vaccination with T cells). Data collected from preclinical studies performed in the experimental autoimmune encephalomyelitis (EAE) model of MS in animals, in vitro cultures of cells from MS patients and the initial results of phase I/II clinical trials are analyzed to better understand which parameters are relevant for obtaining an efficient cell-based therapy for MS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Comparative transcriptomic profile of tolerogenic dendritic cells differentiated with vitamin D3, dexamethasone and rapamycin

  • Navarro-Barriuso, Juan|||0000-0003-2884-4961
  • Mansilla Lopez, Maria Jose|||0000-0002-5044-6313
  • Naranjo-Gómez, Mar
  • Sánchez, Alex|||0000-0002-8673-7737
  • Quirant, Bibiana|||0000-0002-3875-8074
  • Teniente Serra, Aina|||0000-0003-3440-804X
  • Ramo-Tello, Cristina|||0000-0001-8643-5053
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
Tolerogenic dendritic cell (tolDC)-based therapies have become a promising approach for the treatment of autoimmune diseases by their potential ability to restore immune tolerance in an antigen-specific manner. However, the broad variety of protocols used to generate tolDC in vitro and their functional and phenotypical heterogeneity are evidencing the need to find robust biomarkers as a key point towards their translation into the clinic, as well as better understanding the mechanisms involved in the induction of immune tolerance. With that aim, in this study we have compared the transcriptomic profile of tolDC induced with either vitamin D3 (vitD3-tolDC), dexamethasone (dexa-tolDC) or rapamycin (rapa-tolDC) through a microarray analysis in 5 healthy donors. The results evidenced that common differentially expressed genes could not be found for the three different tolDC protocols. However, individually, CYP24A1, MUCL1 and MAP7 for vitD3-tolDC; CD163, CCL18, C1QB and C1QC for dexa-tolDC; and CNGA1 and CYP7B1 for rapa-tolDC, constituted good candidate biomarkers for each respective cellular product. In addition, a further gene set enrichment analysis of the data revealed that dexa-tolDC and vitD3-tolDC share several immune regulatory and anti-inflammatory pathways, while rapa-tolDC seem to be playing a totally different role towards tolerance induction through a strong immunosuppression of their cellular processes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Searching for the Transcriptomic Signature of Immune Tolerance Induction-Biomarkers of Safety and Functionality for Tolerogenic Dendritic Cells and Regulatory Macrophages

  • Navarro-Barriuso, Juan|||0000-0003-2884-4961
  • Mansilla Lopez, Maria Jose|||0000-0002-5044-6313
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
The last years have witnessed a breakthrough in the development of cell-based tolerance-inducing cell therapies for the treatment of autoimmune diseases and solid-organ transplantation. Indeed, the use of tolerogenic dendritic cells (tolDC) and regulatory macrophages (Mreg) is currently being tested in Phase I and Phase II clinical trials worldwide, with the aim of finding an effective therapy able to abrogate the inflammatory processes causing these pathologies without compromising the protective immunity of the patients. However, there exists a wide variety of different protocols to generate human tolDC and Mreg and, consequently, the characteristics of each product are heterogeneous. For this reason, the identification of biomarkers able to define their functionality (tolerogenicity) is of great relevance, on the one hand, to guarantee the safety of tolDC and Mreg before administration and, on the other hand, to compare the results between different cell products and laboratories. In this article, we perform an exhaustive review of protocols generating human tolDC and Mreg in the literature, aiming to elucidate if there are any common transcriptomic signature or potential biomarkers of tolerogenicity among the different approaches. However, and although several effectors seem to be induced in common in some of the most reported protocols to generate both tolDC or Mreg, the transcriptomic profile of these cellular products strongly varies depending on the approach used to generate them.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Vitamin D receptor, STAT3, and TET2 cooperate to establish tolerogenesis

  • Català-Moll, Francesc|||0000-0002-2354-8648
  • Ferreté-Bonastre, Anna G|||0000-0003-3327-6129
  • Godoy-Tena, Gerard|||0000-0003-3832-5794
  • Morante-Palacios, Octavio|||0000-0002-6435-2756
  • Ciudad, Laura|||0000-0002-5219-6792
  • Barberà, Laura|||0000-0002-0883-657X
  • Fondelli, Federico|||0000-0002-6875-4744
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
  • Rodríguez-Ubreva, Javier|||0000-0003-4707-4536
  • Li, Tianlu|||0000-0001-7152-4870
  • Ballestar, Esteban|||0000-0002-1400-2440
The active form of vitamin D, 1,25-dihydroxyvitamin D3, induces a stable tolerogenic phenotype in dendritic cells (DCs). This process involves the vitamin D receptor (VDR), which translocates to the nucleus, binds its cognate genomic sites, and promotes epigenetic and transcriptional remodeling. In this study, we report the occurrence of vitamin D-specific DNA demethylation and transcriptional activation at VDR binding sites associated with the acquisition of tolerogenesis in vitro. Differentiation to tolerogenic DCs associates with activation of the IL-6-JAK-STAT3 pathway. We show that JAK2-mediated STAT3 phosphorylation is specific to vitamin D stimulation. VDR and the phosphorylated form of STAT3 interact with each other to form a complex with methylcytosine dioxygenase TET2. Most importantly, pharmacological inhibition of JAK2 reverts vitamin D-induced tolerogenic properties of DCs. This interplay among VDR, STAT3, and TET2 opens up possibilities for modulating DC immunogenic properties in clinics.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Transfection of Vitamin D3-Induced Tolerogenic Dendritic Cells for the Silencing of Potential Tolerogenic Genes. Identification of CSF1R-CSF1 Signaling as a Glycolytic Regulator

  • Mansilla Lopez, Maria Jose|||0000-0002-5044-6313
  • González-Larreategui, Íñigo|||0000-0002-0959-8497
  • Figa-Martín, Neus
  • Barallat, Jaume|||0000-0003-3493-5958
  • Fondelli, Federico|||0000-0002-6875-4744
  • Sellés-Rius, Ares|||0000-0002-9745-7749
  • Quirant, Bibiana|||0000-0002-3875-8074
  • Teniente Serra, Aina|||0000-0003-3440-804X
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
The use of autologous tolerogenic dendritic cells (tolDC) has become a promising strategy to re-establish immune tolerance in autoimmune diseases. Among the different strategies available, the use of vitamin D3 for the generation of tolDC (VitD3-tolDC) has been widely tested because of their immune regulatory properties. To identify molecules and pathways involved in the generation of VitD3-tolDC, we established an easy and fast gene silencing method based on the use of Viromer blue to introduce siRNA into monocytes on day 1 of culture differentiation. The analysis of the effect of CD209 (DC-SIGN) and CD115 (CSF1R) down-modulation on the phenotype and functionality of transfected VitD3-tolDC revealed a partial role of CD115 in their tolerogenicity. Further investigations showed that CSF1R-CSF1 signaling is involved in the induction of cell metabolic reprogramming, triggering glycolysis to produce high amounts of lactate, a novel suppressive mechanism of T cell proliferation, recently found in autologous tolerogenic dendritic cells (ATDCs).